The interest around Hsp90 and B-Raf as partners in polypharmacology strategies has also been further explored more recently within an effort to identify ligands endowed with Hsp90/PDHK1/B-Raf multi-target activity.89 The identification of compounds with such a tailored polypharmacology profile would enable the modulation of multiple pathways important to survival and proliferation of tumor cells, thus resulting in more effective anticancer therapies. Here, BRAF is linked to neoplasm.